申请人:Suzuki Yuichi
公开号:US20050256103A1
公开(公告)日:2005-11-17
The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical:
wherein R
1
and R
2
are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R
3
represents a hydrogen atom or the like; and R
6
represents a hydrogen atom or the like.
It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.
本发明涉及以下公式所代表的化合物,其药学上可接受的盐,或其作为药物的用途:
其中R1和R2是相邻的取代基,与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物,该基可能被1至4个取代基所取代,所述取代基选自(1)氧代基,(2)羟基等;R3代表氢原子或类似物;R6代表氢原子或类似物。
本发明的目的是发现一种用于治疗或预防下尿道症状,特别是涉及尿液储存的症状的药剂,该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。